Clinical Trials
28 trialsVandevol
University Hospital, Lille
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Amgen
Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia
Medical College of Wisconsin
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma
Wake Forest University Health Sciences
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
AML1208
Gruppo Italiano Malattie EMatologiche dell'Adulto
AML
Sumitomo Pharma Co., Ltd.
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
University of Chicago
Brentuximab Vedotin + Re-induction Chemotherapy for AML
Massachusetts General Hospital
Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
University of Chicago
UPCC 02407
Abramson Cancer Center at Penn Medicine
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Case Comprehensive Cancer Center
Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone
M.D. Anderson Cancer Center
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Wake Forest University Health Sciences
Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia
Dartmouth-Hitchcock Medical Center
Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer
University of California, San Francisco
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Lenalidomide Plus Chemotherapy for AML
Massachusetts General Hospital
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Case Comprehensive Cancer Center
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Children's Oncology Group
Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia
National Cancer Institute (NCI)
Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer
Fred Hutchinson Cancer Center